Pictet Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Pictet Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268M	Buy	539,255 +201,686	+60%	+$89.4M	0.26%	97
2026 Q1	$150M	Sell	337,569 -414,856	-55%	-$193M	0.16%	160
2025 Q4	$342M	Sell	752,425 -39,033	-5%	-$16.8M	0.33%	68
2025 Q3	$311M	Buy	791,458 +55,636	+8%	+$23.3M	0.3%	83
2025 Q2	$327M	Buy	735,822 +74,635	+11%	+$34.4M	0.33%	80
2025 Q1	$322M	Buy	661,187 +141,519	+27%	+$65.9M	0.36%	76
2024 Q4	$209M	Buy	519,668 +1,665	+0.3%	+$772K	0.23%	111
2024 Q3	$240M	Sell	518,003 -45,353	-8%	-$21.8M	0.26%	99
2024 Q2	$264M	Sell	563,356 -434,938	-44%	-$189M	0.3%	82
2024 Q1	$417M	Sell	998,294 -82,752	-8%	-$35M	0.45%	51
2023 Q4	$440M	Buy	1,081,046 +22,231	+2%	+$8.21M	0.49%	47
2023 Q3	$368M	Buy	+1,058,815	New	+$370M	0.45%	54

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Pictet Asset Management's VRTX Position: Q2 2026 in Review

Pictet Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 60% in Q2 2026, buying an estimated $89.4M and bringing the position to 539,255 shares worth $268M. The position accounts for 0.26% of the portfolio, ranked #97.

Pictet Asset Management first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $440M in Q4 2023. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Pictet Asset Management held 539,255 shares of Vertex Pharmaceuticals worth $268M as of Q2 2026.
Pictet Asset Management bought 201,686 Vertex Pharmaceuticals shares in Q2 2026, an estimated $89.4M.
Vertex Pharmaceuticals made up 0.26% of Pictet Asset Management's portfolio in Q2 2026, its #97 holding.
Pictet Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Pictet Asset Management's Vertex Pharmaceuticals position peaked at $440M in Q4 2023.
1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.